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Abstract
Objectives: The current study aims to find the differences between glioblastoma 
multiforme (GBM) and giant cell glioblastoma (GCG) regarding mortality and progno‐
sis among adults and elderly patients in the U.S.
Methods and Materials: This study is a historical cohort type of study and is con‐
ducted on adults and elderly individuals with GBM or GCG from the years 1985–
2014 in the U.S. Data were collected from the Surveillance, Epidemiology, and End 
Results Program (SEER) database. The study exposure was GBM or GCG and the 
outcome was mortality. The potential confounders were age, sex, race, ethnicity, year 
of diagnosis, primary site, brain overlap, and surgery. A chi‐square test was used for 
categorical data. A univariate analysis was used for variables having a p‐value <.05. 
Potential confounders were selected and evaluated using multivariate logistic regres‐
sion models to calculate the odds ratio with stepwise selection.
Results: The study sample was 25,117. The incidences of GBM and GCG were not 
similar in relation to age group. Also, Spanish–Hispanic ethnicity was independently 
protective of GBM and GCG as compared to Non‐Spanish–Hispanic ethnicity pa‐
tients with GBM have a higher mortality rate than do GCG patients. The mortality 
rate was higher among patients diagnosed before 2010.
Conclusion: GCG was not statistically significant in association to reduced mortal‐
ity. Non‐Spanish–Hispanics with GBM or GCG had a higher mortality rate than did 
Spanish–Hispanics. Factors such as being female, being age 59–65, and having a year 
of diagnosis before 2010 were independently associated with increased mortality.
K E Y W O R D S
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1  | INTRODUC TION
Brain cancer and other nervous system cancers are the tenth leading 
cause of death in the U.S. Brain cancer is common among adults and 
elderly individuals (SEER Program). Giant cell glioblastoma (GCG) is 
a rare neoplasm characterized by a predominance of bizarre multi‐
nucleated giant cells with abundant eosinophilic cytoplasm. (Ohgaki, 
Peraud, Nakazato, Watanabe, & Deimling, 2000).
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Significant efforts to characterize this unusual malignancy have 
established a glial origin, and it is now considered a subtype of glio‐
blastoma multiforme (GBM; Akslen, Mork, Larsen, & Myrseth, 1988; 
Becker, Benyo, & Roessmann, 1967; Hadfield & Silverberg, 1972; Katoh 
et al., 1995; Kawano et al., 1995; Margetts & Kalyan‐Raman, 1989).
GCG has been reported to represent between 2% and 5% of 
GBM cases (Artico, Cervoni, Celli, Salvati, & Palma, 1993; Palma, 
Celli, Maleci, Di Lorenzo, & Cantore, 1989; Shinojima et al., 2004).
Importantly, several small series and case reports have sug‐
gested that the prognosis of GCG is significantly better than that 
observed for GBM (Akslen et al., 1988; Becker et al., 1967; Burger 
& Vollmer, 1980; Chang, Kuwana, Ito, Koike, & Kitamura, 2001; Deb, 
Sharma, Chander, Mahapatra, & Sarkar, 2006; Gullotta, Casentini, & 
Neumann, 1980; Klein, Molenkamp, Sorensen, & Roggendorf, 1998; 
Kroh, Matyja, Marchel, & Bojarski, 2004; Margetts & Kalyan‐Raman, 
1989; Sabel, Reifenberger, Weber, Reifenberger, & Schmitt, 2001; 
Shinojima et al., 2004). The development of GBG is highly related to 
mutations of the TP53 gene (Kleihues & Glioblastoma,)
MGMT promoter methylation, mutations in the IDH1/2 genes, 
or BRAF mutations, which are actually used as diagnostic, prog‐
nostic, and predictive molecular markers in anaplastic glial tumors 
(Lohkamp et al., 2016).
Glioblastoma multiforme is a common malignant tumor that orig‐
inates from astrocytes. It is a rapid‐growing tumor that affects the 
nervous system, including the brain and the spinal cord (GBM, 2017).
It is estimated that GBM cases in the U.S. account for approxi‐
mately 20% of all primary CNS tumors in the adult population and 
almost 75% of all anaplastic gliomas (Nizamutdinov et al., 2018). 
Glioblastoma multiforme is the most lethal primary malignant 
central nervous system tumor in adults (Li et al., 2015; Ohgaki & 
Kleihues, 2005; Stupp, Mason, & Bent, 2005). GBM incidence and 
prognosis have changed over the past few years. This has been 
explained by several risk factors, such as sex, age group, race, eth‐
nicity, year of diagnosis, primary site, and surgical removal of the 
tumor (Pietschmann et al., 2015; Stummer et al., 2008). It has been 
found that the overall prognosis of patients with GBM is poor, 
with a median survival of 14.6 months and a five‐year survival rate 
of <5% (Ostrom et al., 2013; Stupp et al., 2005). A review of the 
relevant literature, which included a well‐conducted systematic 
review (Beyer et al., 2016), provided evidence of an association 
between survival in cases of glioblastoma and several prognos‐
tic factors, including age at diagnosis, sex, race/ethnicity, primary 
site, and treatment (including surgery). However, no information 
was available about the effect of subtypes of glioblastoma and 
prognosis, particularly in terms of whether survival in cases of 
giant cell glioblastoma was different from that in cases of other 
subtypes of glioblastoma multiforme. Kozak and Moody (2009) 
conducted a study using the Surveillance, Epidemiology, and End 
Results (SEER) database from 1988–2004, with which they made 
a comparison between GCG and GBM and found that GCG had a 
better prognosis. The present study included samples from 1985 
to 2014 to discover the difference in prognosis between glioblas‐
toma subtypes after the evolution of treatment modalities over 
the past few years. Therefore, the current study aimed to find the 
differences between GBM and GCG regarding mortality and prog‐
nosis among adults and elderly patients in the U.S.
2  | MATERIAL S AND METHODS
2.1 | Study strategy and data source
A historical cohort was assembled using data from the Surveillance, 
Epidemiology, and End Results (SEER) database in July 2017 (http://
www.seer.cancer.gov/). The data were collected via SEER*Stat soft‐
ware from 1985 to 2014. The SEER program was established in 1973 
by the U.S. NCI and collects incidences and survival records of pa‐
tients with malignant tumors from 18 population‐based cancer reg‐
istries in the U.S. (SEER). The registries represent approximately 28% 
of the population of the U.S.; registries were selected, in part, for 
their diverse population subgroups. These surveys have multistage 
sampling and are considered to be complex, overestimated, and not 
representative of the entire U.S. population. However, SEER does its 
own modeling through extrapolation.
2.2 | Study population
Patients aged younger than 20 years have a lower incidence rate; 
frequency rapidly increases starting in the fifth decade of life 
(Furnari et al., 2007). Therefore, the inclusion criteria for the analy‐
sis were patients with a confirmed diagnosis of GBM or GCG at age 
18 to 65 from the years 1985–2014. The exclusion criteria included 
insurance, grading, and tumor size, due to a high percentage (over 
25%) of missing data in the SEER database. The SEER database in‐
cluded patients’ insurance data from the years 2007 and onwards. 
Also, in terms of tumor size, 65% of data was missing in the data‐
base. However, glioblastoma has no clear grading system, as it is a 
type of glioma and is considered the most malignant type (type 4). 
Therefore, grading was also excluded (http://www.brain life.org/
abstr act/2017/Mesfin_F1707 15.pdf).
2.3 | Study variables
The study variables included data of GBM patients (histology codes: 
ICD‐O‐3:9440/3, 9441/3) with tumors located in several locations: 
supratentorial (cerebrum, frontal lobe, temporal lobe, parietal lobe, 
occipital lobe), brain overlap, and infratentorial (cerebellum, ventri‐
cle, and brainstem). In addition, primary site codes (C71.0‐C72.0) 
were extracted from the SEER database. Figure 1 shows the vari‐
ables that were analyzed.
In addition, the SEER research data record description was used 
to categorize other variables such as race, which was categorized 
into White, Black, and Others. Ethnicity was also categorized into 
Non‐Spanish–Hispanic–Latino and Spanish–Hispanic–Latino. Year 
of diagnosis was categorized into years before 2010 and years 2010–
2014 due to the approval of Bevacizumab for recurrent glioblastoma 
in 2010 (Johnson, Leeper, & Uhm, 2013).
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2.4 | Statistical analysis
First, the population was selected from the SEER database. Then, 
the characteristics of the population were described. After that, the 
general distribution of the data was examined. Next, some variables 
were transformed into appropriate categories (e.g., group was cat‐
egorized into adults from 18 to 65 years old and elderly individuals 
59–65 years old; Li et al., 2017). The primary site was categorized 
into supratentorial, brain overlap (including the brain ventricles and 
other unspecified brain locations), and infratentorial regions.
The alpha level was set at 0.2 due to the small sample size of GCG 
incidences in the SEER database.
A chi‐square test was used for categorical data. Categorical data were 
expressed by numbers (n) and percentage (%). A univariate analysis was 
used for variables having a p‐value < .05, while potential confounders (pa‐
tient's sex, age group, race, ethnicity, year of diagnosis, primary site, brain 
overlap, and surgery) were selected and evaluated by multivariate logistic 
regression models to calculate the odds ratio with stepwise selection. A 
collinearity model was used to determine the relationship between each 
of the confounders for the exclusion of dependent variables. However, 
no significant relationship between the confounders was excluded.
2.5 | Ethical considerations
Ethical approval was waived, since the analysis was considered non‐
human subjects research by the Florida International University 
Health Science Institutional Review Board.
3  | RESULTS
The study sample was 25,117. It included 24,909 patients with GBM 
and 208 with GCG. However, 88.3% of patients with GBM died 
within a few years, while 84.1% of GCG patients also died from the 
tumor. The baseline characteristics of the study sample are explained 
in Table 1, which shows that gender has a slight variation in GBM and 
GCG incidences. Males are more likely to develop GBM than GCG; 
conversely, females are more likely to develop GCG. Table 1 also 
shows that the incidence of GBM and GCG is not similar in relation 
to age group. Hence, it is statistically significant that adults have a 
higher predisposition to developing GCG than GBM.
Race also reveals some variations in terms of the two subtypes 
of glioblastoma, with individuals who have a white racial back‐
ground being more prone to GBM, while individuals of other races 
being more prone to GCG. The Non‐Spanish–Hispanic–Latino eth‐
nicity has a slightly higher incidence of GBM than GCG, while, in‐
versely, Spanish–Hispanic–Latinos have fewer incidences of GBM 
than GCG. The incidence of GBM was slightly higher than the inci‐
dence of GCG before 2010; after 2010, the incidence of GCG was 
higher. However, incidences of both tumors have decreased con‐
siderably since 2010.
The study reveals some statistically significant differences in 
terms of tumor primary site, with high statistical significance. Both 
subtypes of tumors originate more often in the supratentorial part 
of the brain than elsewhere in the central nervous system. However, 
GCG tumors originate more from the supratentorial site than do 
GBM tumors. It is also statistically significant that GBM risk is higher 
in patients with no surgery or no gross total resection, while patients 
with gross total resection (GTR) have an elevated GCG risk. Table 2 
shows that patients with GBM have a higher mortality rate than do 
GCG patients. Table 3 shows that GCG has an odds ratio [OR] of 
0.56 with a confidence interval of 0.53–1.44, which is independently 
associated with reduced mortality.
Table 2 also shows a slight difference in mortality between age 
groups in relation to the two glioblastoma subtypes; this differ‐
ence is statistically significant. It indicates that elderly patients 
F I G U R E  1   Variables were analyzed 
using the SEER database and Stata 
software
Independent:
Glioblastoma Mulforme (GBM) and 
Giant Cell Glioblastoma (GCG)
Dependent:
Mortality
Potenal Confounders:
Sex
Age group
Race
Ethnicity
Year of diagnosis
Primary site
Surgery
Brain overlap
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have a worse prognosis than do adults. Glioblastoma patients 
with a white racial background also face a slightly increased risk 
of death. The Spanish–Hispanic–Latino ethnicity has a lower mor‐
tality rate than do Non‐Spanish–Hispanic–Latinos, as explained in 
Table 3. The Spanish–Hispanic–Latino ethnicity is independently 
protective from GBM and GCG (OR 0.63, CI = 0.52–0.77). GBM 
and GCG tumors with brain overlap have a statistically significant 
worse outcome than do other primary tumor sites, as shown in 
Table 2.
Surgery also plays a role in patients’ outcomes. The mortality 
rate increases in patients with no tumor resection. As shown in 
Table 3, the factors independently associated with increased mor‐
tality are: being female ([OR] 1.12, CI = 1.01–1.25), being age 59 
to 65 years (OR 1.64, CI = 1.48–1.82), and being diagnosed earlier 
than 2010 (OR 5.26, CI = 4.74–5.84). Table 4 shows some second‐
ary findings of the study.
4  | DISCUSSION
To the best of our knowledge, this study is one of the few that 
address the association of subtype of glioblastoma and mortality 
in adults in the U.S. after 2010 and that involves a large sample 
size in GCG and GBM with the utilization of ICD‐0‐3 codes. GBM 
is more common than GCG and has a higher mortality rate. On 
the other hand, the current study provides statistically significant 
data about ethnicity, explaining that the Spanish–Hispanic–Latino 
ethnicity is independently protective from both glioblastoma 
subtypes as compared to the Non‐Spanish–Hispanic ethnicity. 
Furthermore, factors like being female, being age 59 to 65, and 
having a year of diagnosis before 2010 are independently associ‐
ated with increased mortality.
This study found that elderly individuals have the highest mor‐
tality rate among GBM and GCG patients in comparison to adults 
(p < .001). Some studies were consistent with the previous findings 
(Hartmann et al., 2010; Lin & Wagner, 2015; Murthy, Krumholz, 
& Gross, 2004; Rong et al., 2016). Therefore, age is considered 
a significant predictor of survival time (Shah, Bista, & Sharma, 
2016). This study also demonstrates that elderly individuals are 
more prone to having GBM than GCG, which explains the rarity of 
GCG. This finding may indicate that the elderly population is more 
susceptible to GBM due to an increased chance that cells will mu‐
tate into cancer cells. The current study demonstrated that more 
TA B L E  1   Baseline characteristics of GBM and GCG patients 
from 1985–2014 in US
Characteristics
Type of glioblastoma
GBM NOS
N (%)
GCG
N (%) p‐Value
Sex
Male 14,375 (57.7) 115 (55.3) .481
Female 10,534 (42.3) 93 (44.7)
Age group
Adults (18–59) 10, 221 (41.0) 120 (57.7) <.001
Elderly (>60) 14,686 (59.0) 88 (42.3)
Race
White 22,700 (91.3) 184 (88.5) .318
Black 1,169 (4.7) 12 (5.8)
Other 994 (4.0) 12 (5.8)
Ethnicity
Non‐Spanish–
Hispanic–Latino
23,791 (95.5) 192 (92.3) .027
Spanish–
Hispanic–Latino
1,118 (4.5) 16 (8)
Year of diagnosis
Before 2010 20,719 (83.3) 171 (82.2) .71
2010–2014 4,190 (16.8) 37 (17.8)
Primary site
Supratentorial 17,828 (71.6) 168 (80.8) <.001
Brain overlap 6,767 (27.2) 33 (15.9)
Infratentorial 314 (1.3) 7 (3.4)
Surgery
None 3,287 (26.1) 13 (11.4) <.001
No GTR 5,719 (45.5) 50 (43.9)
GTR 3,574 (28.4) 51 (44.7)
Abbreviations: GBM, glioblastoma multiforme; GCG, giant cell glioblas‐
toma; GTR, gross total resection; NOS, not otherwise specified.
TA B L E  2   Mortality rate of GBM and GCG patients from 
1985–2014 in US
Characteristics
Mortality
p‐Value
Alive
N (%)
Dead
N (%)
Glioblastoma
GBM 2,916 (11.7) 21,993 (88.3) .064
GC 33 (15.9) 175 (84.1)
Sex
Male 1,778 (12.3) 12,703 (87.7) <.001
Female 1,162 (10.9) 9,465 (89.1)
Age group
Adults 1,464 (14.2) 8,877 (85.8) <.001
Elderly 1,483 (10.0) 13,291 (90.0)
Race
White 2,534 (11.1) 20,350 (88.9) <.001
Black 200 (16.9) 981 (83.1)
Others 198 (19.7) 808 (80.3)
Ethnicity
Non‐Spanish–
Hispanic
2,741 (11.4) 21,242 (88.6) <.001
Spanish–
Hispanic–Latino
208 (18.3) 926 (81.7)
Abbreviations: GBM, glioblastoma multiforme; GCG, giant cell 
glioblastoma.
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males are afflicted with GBM than with GCG, while more females 
are afflicted with GCG (p = .481), consistent with (Colen, Wang, 
Singh, Gutman, & Zinn, 2015; Matsuda et al., 2011; Nizamutdinov 
et al., 2018; Ohgaki et al., 2004; Shinojima et al., 2004; Verger et 
al., 2011). Another study, conducted on Black patients with GBM, 
showed that Black males were affected by GBM more than were 
Black females (Loukas, 2014). Therefore, GCG, an uncommon type 
of glioblastoma multiforme, more often affects females. However, 
GBM affects males more than females, regardless of race. The 
previous findings may be explained by genetic factors.
The present study stated that the mortality rate is higher among 
GBM and GCG patients diagnosed before 2010 (p < .001). Also, one 
study showed that the prognosis for elderly patients with glioblas‐
toma has improved since the introduction of the Stupp regimen (i.e., 
radiotherapy plus concomitant and adjuvant temozolomide) in 2005 
(Shah et al., 2016). This indicates that year of diagnosis has a signifi‐
cant impact on the prognosis of glioblastoma patients. However, the 
proportion of patients with GBM is slightly higher than the propor‐
tion of GCG patients before 2010. On the other hand, the proportion 
of GCG incidences is slightly higher than the proportion of GBM inci‐
dences after 2010 (p = .71).
Patients who did not have a GTR have a higher mortality rate 
(p < .001). Moreover, patients who had not undergone surgery or 
GTR developed GBM more often than they did GCG (p < .001).
Studies like (Koul, Dubey, Torri, Kakumanu, & Goyal, 2012; Pan, 
Ferguson, & Lam, 2015) had similar findings, stating that GTR has a 
better survival rate than does partial resection or biopsy. Brain over‐
lap GBM and GCG tumors are associated with higher mortality rates 
than are supratentorial and infratentorial tumors (p < .001). This 
finding was similar in one study (Becker et al., 1967).
However, another study showed that the median survival time for 
both cerebellar GBM (cGBM) and supratentorial GBM (sGBM) patients is 
8 months, though sGBM had a worse prognosis as the study progressed 
(Jeswani et al., 2013). Also, patients with brain overlap tumors have a 
higher tendency to develop GBM than GCG (p < .001). Because GBM 
is more common than GCG, it affects brain overlap regions more than 
supra‐ and infratentorial regions (which are affected more by GCG, 
p < .001). This accounts for the higher mortality rate. Non‐Spanish–
Hispanic people have a higher mortality rate from GBM (88.6%, p < .001). 
In addition, a study done on Americans with glioblastoma suggested 
that Latinos tend to have a lower incidence of GBM and present slightly 
younger than non‐Latino Whites (Shabihkhani et al., 2017).
However, white people were found to have the highest incidence 
of death from GBM and GCG as compared to individuals of other 
races (p < .001).
4.1 | Limitations
Unfortunately, SEER registry has some unregistered variables, un‐
derreported and missing data regarding surgery followed by chemo‐ 
or radiotherapy. There were also different styles in data coding and 
Characteristics
Unadjusted Adjusteda
OR (95% CI) N OR (95% CI) N
Glioblastoma
GBM Reference    
GCG 0.70 (0.5–1.02) 25,117 0.88 (0.53–1.44) 12,694
Abbreviations: CI, confidence interval; GBM, glioblastoma multiforme; GCG, giant cell glioblas‐
toma; OR, odds ratio.
aAdjusted for age, sex, race, ethnicity, year of diagnosis, primary site surgery. 
TA B L E  3   Odds ratio of GBM and GCG 
patients from 1985–2014 in US
Characteristics
Unadjusted Adjusted
OR (95% CI) p‐Value OR (95% CI) p‐Value
Race
White REF    
Black 0.61 (0.52–0.71) <.001 0.64 (0.52–0.79) <.001
Others 0.50 (0.43–0.60) <.001 0.61 (0.50–0.75) <.001
Ethnicity
Non‐Spanish–Hispanic REF    
Spanish–Hispanic–Latino 0.57 (0.49–0.67) <.001 0.63 (0.52–0.77) <.001
Year of diagnosis
Before 2010 5.44 (5.01–5.91) <.001 5.26 (4.74–5.84) <.001
2010–2014 REF    
Abbreviations: CI, confidence interval; OR, odds ratio.
TA B L E  4   Secondary findings of race/
ethnicity and the year of diagnosis
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reporting, and movement of patients in and out of SEER registry 
areas.
Furthermore, SEER database may have been affected by the 
selection bias. In which, prospective studies might be influenced as 
well. For example, immortal time bias in the assessment of surgery 
followed by chemo‐ or radiotherapy effectiveness.
5  | CONCLUSIONS
GCG was not statistically significant in terms of its association with 
reduced mortality. Factors such as being female, being age 59 to 65, 
and having a year of diagnosis before 2010 were independently as‐
sociated with increased mortality. The Spanish–Hispanic ethnicity 
was independently protective from GBM and GCG as compared to 
the Non‐Spanish–Hispanic ethnicity. Additional studies should be 
conducted on GBM and GCG patients with the inclusion of important 
factors such as tumor size/activity, disease stage, treatment history, 
and insurance.
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